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Accepted 12 March 2012AbstractObjective: Amniocentesis is a popular and effective prenatal diagnostic tool for chromosomal disorders. It is well-established that the risk of
chromosomal abnormalities increases with maternal age; however, other related indications are seldom reported. Herein, we report our 30-year
experience with amniocentesis from a single medical center, focusing on the indications and rates of abnormality.
Material and Methods: A retrospective review of 16,749 pregnant women in the mid-trimester between January 1981 and December 2010 was
conducted. The medical records were analyzed.
Results: The indications for amniocentesis were advanced maternal age ( 34 years old) (n¼ 10,970, 65.5%), increasing-risk maternal triple-
marker Down’s screening test ( 1/270) (n¼ 2090, 12.5%), history of abnormal offspring birth (n¼ 792, 4.7%), abnormal ultrasound findings
(n¼ 484, 2.9%), parent with abnormal karyotype (n¼ 252, 1.5%), family history of chromosomal abnormality (n¼ 183, 1.1%), drug and
radiation exposure (n¼ 165), abnormal chorionic villus sampling (CVS) results (n¼ 25), intrauterine fetal death (n¼ 50), and other non-specific
causes (n¼ 1662, 9.9%). The rate of abnormality for each indication was 16% in the abnormal CVS group, 12% in the intrauterine fetal death
group, 11.5% for parental chromosomal abnormality, 8.7% in the abnormal ultrasound finding group, 3.0% in the increasing-risk maternal triple-
marker Down’s screening test group, 2.5% in the advanced maternal age group, 1.5% for other non-specific causes, 1.4% for history of abnormal
offspring birth, and 1.1% for family history of chromosomal abnormality.
Conclusions: Both parents with abnormal karyotype and abnormal ultrasound findings are indications for which consideration of further
amniocentesis is highly recommended.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Amniocentesis for genetic diagnosis began in the late 1960s
and early 1970s as a tertiary procedure reserved for only the
highest-risk patients [1,2]. Although this procedure is familiar
in clinical practice, the main role of amniocentesis continues
to be the detection of chromosomal abnormalities and well-
known clinically evident or hereditary genetic diagnoses
[3e8]. Amniocentesis is often used with women of ancs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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younger women ( 1/270) who have undergone maternal
blood Down’s syndrome screening [2]. However, not all
amniocentesis cases are performed under the above-mentioned
indications.
There are very few studies available that discuss indications
other than AMA or for other chromosomal disorders. Papers in
Canada [9] and Korea [10] have shown that if amniocentesis is
performed for couples with a history of abnormal offspring
birth or abnormal ultrasound findings, the abnormality rate of
amniocentesis is high. Domestic data from Hsieh et al showed
that ultrasound and maternal serum a-fetoprotein should be
added to the list to increase the efficacy of genetic amnio-
centesis [11]. In another study, Tseng et al shared their 10-year
experience with amniocentesis, suggesting the highest detec-
tion rate was found in cases with abnormal ultrasound findings
[12]. However, studies addressing the various kinds of indi-
cations for amniocentesis are still rare. This study, based on
16,749 amniocentesis cases in a single tertiary medical center
from 1981 to 2010, will be of value for those women who need
genetic counseling in Taiwan.
Materials and methods
Data were obtained from amniocentesis records of the
cytogenetic laboratory at Taipei Veterans General Hospital,
a tertiary medical center, between 1981 and 2010. The detailed
information of indications for prenatal diagnosis of chromo-
somal abnormality with cytogenetic analysis included: (1)
AMA, that is, if the mother was  34 years at the expected
date of confinement; (2) abnormal chorionic villus sampling
(CVS) results; (3) abnormal biochemical markers in maternalFig. 1. The annual distribution of total cases of amserum, such as maternal blood Down’s syndrome screening (
1/270); (4) abnormal ultrasound findings; (5) intrauterine fetal
death (IUFD); (6) family history of chromosomal abnormali-
ties; (7) parent with abnormal karyotype; (8) history of
abnormal offspring birth; (9) radiation or medication exposure
during pregnancy; and (10) other non-specific indications,
such as anxiety, consanguineous marriage, and so on.
Chromosomal abnormalities detected by amniocentesis
were classified into: (1) autosomal chromosome aneuploidies;
(2) sex chromosome aneuploidies; (3) structural rearrange-
ments (reciprocal translocation, Robertsonian translocation,
balanced translocations, unbalanced translocations, inversions,
insertions, deletions, isochromosome, ring chromosome and
marker chromosomes); and (4) mosaicism.
The frequency of the different types of abnormalities was
calculated according to each indication, and the detection rate
for abnormal cytogenetic findings in various indications was
estimated.
Results
Analysis was carried out on 16,749 amniocentesis cases
dating from 1981 to 2010. Total chromosome aberrations were
detected in 455 cases (2.72%), with 2.72% overall positive
rates of abnormal cytogenetic findings (455/16,749). The
annual amniocentesis numbers and the abnormal numbers are
shown in Fig. 1. As shown in Fig. 2, the indications of
abnormal biochemical markers, besides AMA, in maternal
serum increased dramatically from 1994. The accumulated
data for the different indications for amniocentesis are shown
from highest to lowest: AMA (65.5%, 10,970/16,749);
abnormal biochemical markers in maternal serum (12.5%,niocentesis and abnormal cytogenetic findings.
Fig. 2. The annual distribution of all indications for amniocentesis.
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16,749); history of abnormal offspring birth (4.7%, 792/
16,749); abnormal ultrasound findings (2.9%, 484/16,749);
parent with abnormal karyotype (1.5%, 252/16,749); family
history of chromosomal abnormalities (1.1%, 183/16,749);
radiation or medication exposure during early pregnancy
(1.0%, 165/16,749); IUFD (0.3%, 50/16,749); and abnormal
CVS results (0.2%, 25/16,749). When the cases with abnormal
CVS results (16%, 4/25) and IUFD (12%, 6/50) were
excluded, the highest detection rates of chromosomal abnor-
malities were in cases with the indications of abnormal
ultrasound findings (8.7%, 42/484) and parental abnormal
karyotypes (11.5%, 29/252). However, the positive predictive
values were not so obvious in cases with AMA (2.5%, 271/
10,970), abnormal biochemical markers in maternal serum
(3.0%, 62/2090), family history of chromosomal abnormality
(1.1%, 2/183), history of abnormal offspring birth (1.4%, 11/
792), medication or radiation exposure (1.8%, 3/165) and
other non-specific indications (1.5%, 25/1662) (Table 1).Table 1
Case number and detection rate of chromosomal aberrations in different indication
Indication Case number (N ) Proportio
AMA 10,970 65.50
Abnormal CVS results 25 0.15
Abnormal serum Down’s 2090 12.48
Abnormal ultrasound findings 484 2.89
IUFD 50 0.30
Family history 183 1.09
Parent with abnormal karyotype 252 1.50
History of abnormal offspring birth 792 4.73
Radiation or medication exposure 165 0.99
Others 1662 9.92
Total 16,749 100
Abnormal serum Down’s¼ increased-risk maternal triple-marker Down’s scree
CVS¼ chorionic villus sampling; family history¼ family history of chromosomalAmong the cases with chromosomal aberrations, 274 were
numerical abnormalities and 181 were structural abnormalities.
For the numerical abnormalities: 2 cases (0.73%) were with
triploidy; 112 (40.88%) with trisomy 21; 49 (17.88%) with
trisomy 18; 9 (3.28%) with trisomy 13; 22 (8.03%) with
mosaic autosomal trisomy; 20 (7.3%) with 45,X; 18 (6.57%)
with 47,XXY; 9 (3.28%) with 47,XXX; 6 (2.19%) with
47,XYY; and 29 (10.58%) with a mosaic sex chromosome
aberration.
For the structural abnormalities: 74 cases (40.9%) were
with reciprocal translocation; 39 (21.6%) with Robertsonian
translocation; 33 (18.2%) with inversion; 12 (6.6%) with
deletion; 2 (1.1%) with duplication; 3 (1.7%) with insertion; 2
(1.1%) with isochromosome; 2 (1.1%) with ring chromosome;
and 14 (7.7%) with marker chromosome (Table 2).
Trisomy 21 was found frequently in women with, in order,
indications of AMA (27.7%), abnormal maternal serum
screening results (30.7%), and a history of abnormal offspring
birth (45.5%); trisomy 18 was noted commonly in cases withs for amniocentesis.
n (%) Abnormal number (n) Frequency of abnormality (%)
271 2.47
4 16
62 2.97
42 8.68
6 12
2 1.09
29 11.51
11 1.39
3 1.82
25 1.50
455 2.72
ning test ( 1/270); AMA¼ advanced maternal age ( 34 years old);
abnormality; IUFD¼ intrauterine fetal death.
Table 2
Proportion of numerical and structural chromosomal abnormalities.
Case number (n) Proportion (%)
Numerical abnormality 274
Triploidy 2 0.73
Trisomy 21 112 40.88
Trisomy 18 49 17.88
Trisomy 13 9 3.28
Mosaic autosomal
chromosome abnormalities
22 8.3
45,X 20 7.3
47,XXY 18 6.57
47,XXX 9 3.28
47,XYY 6 2.19
Mosaic sex chromosome
abnormalities
29 10.58
Structural abnormality 181
Reciprocal translocation 74 40.88
Robertsonian translocation 39 21.55
Inversion 33 18.23
Deletion 12 6.63
Duplication 2 1.1
Insertion 3 1.66
Isochromosome 2 1.1
Ring chromosome 2 1.1
Marker chromosome 14 7.73
Total 455 100
Table 3
Frequencies and types of numerical chromosomal abnormalities according to diffe
Anomaly Amniocentesis in the diff
AMA Abnormal
CVS result
Abnormal
serum
Down’s
Abnormal
ultrasound
findings
Triploidy 1 (0.4%) 0 0 0
Autosomal trisomy
Trisomy 21 75 (27.7%) 0 19 (30.7%) 6 (14.3%)
Trisomy 18 31 (11.4%) 0 3 (4.8%) 11 (26.2%)
Trisomy 13 7 (2.6%) 0 0 2 (4.8%)
Mosaic 16 (5.9%) 0 1 (1.6%) 0
Sex Chromosome
45,X 6 (2.2%) 0 1 (1.6%) 12 (28.6%)
47,XXY 14 (5.17%) 1 (25%) 2 (3.2%) 0
47,XXX 5 (1.9%) 1 (25%) 2 (3.2%) 0
47,XYY 6 (2.2%) 0 0 0
Mosaic 19 (7.0%) 0 6 (9.7%) 0
Translocation
Reciprocal 39 (14.4%) 1 (25%) 9 (14.5%) 3 (7.1%)
Robertsonian 16 (5.9%) 0 4 (6.5%) 4 (9.5%)
Inversion 20 (7.4%) 0 7 (11.3%) 0
Deletion 6 (2.2%) 0 1 (1.6%) 2 (4.8%)
Duplication 2 (0.7%) 0 0 0
Insertion 1 (0.4%) 0 0 1 (2.4%)
Isochromosome 1 (0.4%) 0 0 1 (2.4%)
Ring chromosome 1 (0.4%) 0 1 (1.6%) 0
Marker chromosome 8 (3.0%) 1 (25%) 3 (4.8%) 0
Total 271 4 62 42
Abnormal offspring birth¼ history of abnormal offspring birth; abnormal serum Do
AMA¼ advanced maternal age ( 34 years old); CVS¼ chorionic villus
IUFD¼ intrauterine fetal death.
209Y.-W. Chang et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 206e211the indications of IUFD (33.3%) and abnormal ultrasound
findings (26.2%); 45,X in cases with the indication of
abnormal ultrasound findings (28.6%); and translocation was
frequently noted in cases with the indication of parental
abnormal karyotype (69.0%) (Table 3).
Discussion
As the risk prediction for other indications remains
controversial, the results from this paper could be used as
a reference to estimate the risk of chromosomal abnormality
based on the couple’s indication for amniocentesis during
prenatal genetic consultation. Amniocentesis is not free of
complications, even though it has become available for
prenatal screening of chromosomal abnormality. Septic abor-
tion might be the most serious complication, although its
occurrence is rare. Other complications include rupture of the
membrane, infection, hematoma, and preterm labor. There-
fore, the necessity of amniocentesis must be considered along
with the risk-benefit ratio.
There is no doubt that AMA contributes to the main indica-
tion of amniocentesis, and it is also well known that the risk of
chromosomal abnormality increases significantly in pregnant
women as they age[13]. Formothers older than 34 years, the risk
ranged from 0.32% to 0.35% for trisomy 21 and 1.3% for all
kinds of chromosomal abnormality [14,15]. In this study, the
main indication for amniocentesis from 1981 to 2010 was AMA
(65.5%), which was compatible with data from multiple studiesrent indications.
erent indications [Number (n) / Frequency (%)]
IUFD Family
history
Parent with
abnormal
karyotype
Abnormal
offspring
birth
Radiation or
medication
exposure
Others
1 (16.7%) 0 0 0 0 0
1 (16.7%) 0 1 (3.5%) 5 (45.5%) 1 (33.3%) 4 (16%)
2 (33.3%) 0 0 0 0 2 (8%)
0 0 0 0 0 0
0 0 1 (3.5%) 0 0 4 (16%)
1 (16.7%) 0 0 0 0
0 0 0 1 (9.1%) 0 0
0 0 0 0 0 1 (4%)
0 0 0 0 0 0
0 0 1 (3.5%) 0 0 3 (12%)
1 (16.7%) 1 (50%) 13 (44.8%) 2 (18.2%) 2 (66.7%) 3 (12%)
0 1 (50%) 7 (24.1%) 2 (18.2%) 0 5 (20%)
0 0 3 (10.3%) 1 (9.1%) 0 2 (8%)
0 0 3 (10.3%) 0 0 0
0 0 0 0 0
0 0 0 0 0 1 (4%)
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 2 (8%)
6 2 29 11 3 25
wn’s¼ increased-risk maternal triple-marker Down’s screening test (1/270);
sampling; family history¼ family history of chromosomal abnormality;
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amniocentesis changed significantly in 1994, becausematernal
blood Down’s syndrome screening became popular at that
time. Popularity of prenatal screening methods increased the
number of amniocentesis cases, and also changed the distri-
bution of various kinds of indications for amniocentesis [10].
The overall rate of chromosome aberration (2.72%),
including the rates of abnormality in groups with AMA,
abnormal maternal serum screening results, and abnormal
ultrasound findings, were very similar to those of previous
studies [10e12,14,17,18]. Table 4 gives a summary of similar
studies. Ultrasound findings might be one of the best indicators
for arranging further amniocentesis, since our study showed
a high positive rate of abnormality when the indication for
amniocentesis was abnormal ultrasound findings (8.7%). This
rate was consistent with the study of Tseng et al (8.9%) [12],
and higher than those from Yang et al (6.5%) [15] and Kar-
aoguz et al (5.3%) [18], but far lower than that from Hsieh et al
(20.3%) [11]. The possible reasons for the significantly high
abnormal amniocentesis findings in the abnormal ultrasound
group in Hsieh et al’s laboratory study might be caused by
selection bias (Hsieh was a pioneer in ultrasound and high-risk
pregnancy), and the other might be the relatively limited
number of cases in their study (n¼ 2975), compared with
16,749 in our study, and 7028 in Tseng et al’s study [12]. In our
study, cases with the indication of IUFD had the highest rate of
abnormality, but the real reason for this is unknown. The
majority of the abnormalities were aneuploidies, which means
that these babies might have a critical genetic abnormality,
resulting in a lethal situation. Of course, this may be an inci-
dental finding, related to the extremely small number of cases.
In this study, we confirmed the value of maternal blood
Down’s syndrome screening in younger women, as up to
3.0% of those with abnormal maternal serum marker indi-
cations for amniocentesis had positive amniocentesis results,
compared with 2.5% of those whose indications were AMA.
Parental abnormal karyotypeswere also a good indicator for
arranging amniocentesis, as confirmed in our study, as up to
11.5% of those whose indication for amniocentesis was
parental abnormal karyotypes had positive amniocentesis
results.
From our data given in this study, patients with the indi-
cations of family history, previous birth of an abnormal child,
radiation or medication exposure, and others, did not have
a greater risk of chromosomal abnormality than the general
population.
AMA is the indication with the highest prediction rate for
numerical abnormality [16], and this was also confirmed in
our study. However, although AMA did not increase the
incidence of structural abnormality [16], our study showed
a 0.86% rate for women with AMA, compared with 0.4% in
all amniocentesis cases, and 0.33% in Caron et al’s study [9].
In our analysis, cases with the indications of AMA and
abnormal maternal serum screening results had a higher
prevalence of trisomy 21. Cases with abnormal ultrasound
findings showed a higher risk for trisomy 18 and 45,X, andT
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a higher risk for translocation.
In conclusion, this paper has presented the largest series of
amniocentesis cases in Taiwan, andmight be useful in estimating
positive amniocentesis results before genetic counseling.
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